1. Applying the Latest Data on Treat-and-Extend Strategies to Clinical Cases in nAMD

3. What Clinicians Need to Know Regarding Treat-and-Extend Regimens

4. Advantages of T&E Regimen Strategy

5. Advantages of T&E over PRN Regimen

6. Injection Schedule for the Recommended Treatment Approach in the First Year of T&E

7. ALTAIR Study: Mean Change in BCVA From Baseline to Week 52

8. ALTAIR Study: Maximum Interval Extension Times

9. The Role of Exudation

10. Results from CATT Trial: IRF

11. FLUID Study: OCT SRF Fluid Determination

12. Clinical Cases in nAMD

13. FIRST CASE SCENARIO: Patient who had been successfully managed on a T&E regimen for some time, but develops exudation without a change in vision

14. When Do You Extend The Interval Period?

16. FIRST CASE SCENARIO, cont

17. SECOND CASE SCENARIO: Patient who was started on a T&E regimen, had some exudation appear during the T&E regimen (eg, at 10 weeks), so the interval was shortened again; but then patient was restarted on T&E and successfully extended to 12 week injections

18. PLANET Study: Aflibercept Monotherapy vs Aflibercept Plus PDT in Patients With PCV

19. EVEREST II: Treatment Schedule

20. SECOND CASE SCENARIO, cont

21. THIRD CASE SCENARIO: Patient successfully managed on a T&E regimen but then misses appointments and shows back up 5-6 months after their last injection

22. THIRD CASE SCENARIO, cont

23. Concluding Remarks

24. Abbreviations